A Study to Learn About the Medicine Called Ritlecitinib in Adults With Severe Alopecia Areata in Real-world Settings
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
123actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-03 | actual | When the study began enrolling |
| Primary completion | 2025-05-30 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-05-30 | actual | The whole study's end, after follow-up |
| First posted | 2025-09-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Severe Alopecia Areata
Intervention
- Drug: Ritlecitinib
Primary outcomes
what the primary-completion date above is the date OF% of patients for whom their clinician was "satisfied" with current control of alopecia areata
measured 11/15/2023 to 06/10/2024
% of patients with clinician-assessed mild, moderate, or severe disease
measured 11/15/2023 to 06/10/2024
% of patients with clinician assessed progressive, stable, or improving disease
measured 11/15/2023 to 06/10/2024
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed